X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Provided By GlobeNewswire
Last update: Aug 8, 2024
First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval
Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024
Read more at globenewswire.com
